{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T21:37:09Z","timestamp":1764020229640},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Sociedad Espa\u00f1ola de Diabetes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s12020-018-1785-z","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T10:21:44Z","timestamp":1539771704000},"page":"316-322","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long-term remission following antithyroid drug withdrawal in patients with Graves\u2019 hyperthyroidism: parameters with prognostic value"],"prefix":"10.1007","volume":"63","author":[{"given":"Ricardo V.","family":"Garc\u00eda-Mayor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"\u00c1lvarez-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Fluiters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,17]]},"reference":[{"key":"1785_CR1","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1210\/er.2002-0020","volume":"24","author":"BS Prabhakar","year":"2003","unstructured":"B.S. Prabhakar, R.S. Bahn, T.J. Smith, Current perspectives on the pathogenesis of Graves\u2019 disease and ophthalmopathy. Endocr. Rev. 24, 802\u2013835 (2003)","journal-title":"Endocr. Rev."},{"key":"1785_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJM200102153440707","volume":"344","author":"I Klein","year":"2001","unstructured":"I. Klein, K. Ojamaa, Thyroid hormones and the cardiovascular system. N. Engl. J. Med. 344, 501\u2013509 (2001)","journal-title":"N. Engl. J. Med."},{"key":"1785_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.4158\/EP.17.3.456","volume":"17","author":"RS Bahn","year":"2011","unstructured":"R.S. Bahn, H.B. Burch, D.S. Cooper, J.R. Garber, M.C. Greenlee, I. Klein, P. Laurberg, I.R. McDougall, V.M. Montori, S.A. Rivkees, D.S. Ross, J.A. Sosa, M.N. Stan, Hyperthyroidism an other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr. Pract. 17, 456\u2013520 (2011)","journal-title":"Endocr. Pract."},{"key":"1785_CR4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1210\/jcem-67-4-656","volume":"67","author":"JL Codaccioni","year":"1988","unstructured":"J.L. Codaccioni, J. Orgiazi, M. Pugeat, R. Roulier, P. Carayon, Lasting remission in patients treated for Graves\u2019 hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. J. Clin. Endocrinol. Metabol. 67, 656\u2013662 (1988)","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"1785_CR5","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1210\/jcem-48-4-572","volume":"48","author":"GF Fenzi","year":"1979","unstructured":"G.F. Fenzi, K. Hashizume, C.P. Roudeboush, L.J. DeGroot, Changes in thyroid-stimulating immunoglobulins during antithyroid therapy. J. Clin. Endocrinol. Metabol. 48, 572\u2013576 (1979)","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"1785_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1365-2265.1980.tb02129.x","volume":"12","author":"R Docter","year":"1980","unstructured":"R. Docter, G. Bos, T.J. Visser, G. Hennemann, Thyrotrophin binding inhibiting immunoglobulins in Graves\u2019 disease before, during and after antithyroid therapy and its relation to long-acting thyroid stimulator. Clin. Endocrinol. 12, 143\u2013153 (1980)","journal-title":"Clin. Endocrinol."},{"key":"1785_CR7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1056\/NEJM198008073030603","volume":"303","author":"AM MacGregor","year":"1980","unstructured":"A.M. MacGregor, M.M. Petersen, S.M. McLachlan, P. Rooke, B.R. Smith, R.R. Hall, Carbimazole and the autoimmune response in Graves\u2019 disease. N. Engl. J. Med. 303, 302\u2013307 (1980)","journal-title":"N. Engl. J. Med."},{"key":"1785_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1210\/jcem-58-1-62","volume":"58","author":"KW Wenzel","year":"1984","unstructured":"K.W. Wenzel, J.R. Lente, Similar effects of thionamide drug and perchlorate on thyroid-stimulating immunoglobulins in Graves\u2019 disease: evidence against an immunosuppressive action of thionamide drugs. J. Clin. Endocrinol. Metabol. 58, 62\u201369 (1984)","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"1785_CR9","first-page":"2986","volume":"81","author":"O Torring","year":"1996","unstructured":"O. Torring, L. Tallstedt, G. Wallin, G. Lundell, J.G. Ljunggren, A. Taube, M. Saaf, B. Hamberger, Graves\u2019 hyperthyroidism: treatment with antithyroid drugs, surgery or radio iodine- a prospective randomized study. J. Clin. Endocrinol. Metabol. 81, 2986\u20132993 (1996)","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"1785_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/thy.1991.1.129","volume":"11","author":"L Wartofsky","year":"1991","unstructured":"L. Wartofsky, D. Glinoer, B. Solomon, S. Nagataki, R. Lagasse, Y. Nagayama, M. Izumi, Differences and similarities in the diagnosis and treatment of Graves\u2019 disease in Europe, Japan and the United States. Thyroid 11, 129\u2013135 (1991)","journal-title":"Thyroid"},{"key":"1785_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3803\/EnM.2013.28.4.275","volume":"28","author":"JH Moon","year":"2013","unstructured":"J.H. Moon, K.H. Yi, The diagnosis and management of hyperthyroidism in Korea: consensus report of the Korean thyroid association. Endocrinol. Metabol. 28, 275\u2013279 (2013)","journal-title":"Endocrinol. Metabol."},{"key":"1785_CR12","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenlee, P. Lauberg, A.L. Maia, S.A. Rivkees, M. Samuels, A. Sosa, M.N. Stan, M.A. Walter, American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26, 1343\u20131421 (2016)","journal-title":"Thyroid"},{"key":"1785_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.endinu.2017.05.006","volume":"64","author":"RV Garc\u00eda-Mayor","year":"2017","unstructured":"R.V. Garc\u00eda-Mayor, Limitations of current thyroid function tests. Endocrinol. Diabet. Nutr. 64, 404\u2013405 (2017)","journal-title":"Endocrinol. Diabet. Nutr."},{"key":"1785_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2265.1989.tb01244.x","volume":"31","author":"AJ Hedley","year":"1989","unstructured":"A.J. Hedley, R.E. Young, S.J. Jones, P.D. Alexander, P.D. Bewsher, Antithyroid drugs in the treatment of hyperthyroidism of Graves\u2019 disease: long-term follow up of 434 patients. Scottish automated follow-up register group. Clin. Endocrinol. 31, 209\u2013218 (1989)","journal-title":"Clin. Endocrinol."},{"key":"1785_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1530\/eje.1.01993","volume":"153","author":"P Abraham","year":"2005","unstructured":"P. Abraham, A. Avenell, C.M. Park, W.A. Watson, J.S. Bevan, Systematic review of drug therapy of Graves\u2019 hyperthyroidism. Eur. J. Endocrinol. 153, 489\u2013498 (2005)","journal-title":"Eur. J. Endocrinol."},{"key":"1785_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1530\/EJE-16-0725","volume":"176","author":"T Struja","year":"2017","unstructured":"T. Struja, H. Fehlberg, A. Kutz, L. Guebelin, C. Degen, B. Mueller, P. Schuetz, Can we predict relapse in Graves\u2019 disease? Results from a systematic review and meta-analysis. Eur. J. Endocrinol. 176, 87\u201397 (2017)","journal-title":"Eur. J. Endocrinol."},{"key":"1785_CR17","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.4158\/EP161350.OR","volume":"22","author":"F Magri","year":"2016","unstructured":"F. Magri, F. Zerbini, M. Gaiti, V. Capelli, A. Ragni, M. Rotondi, L. Chiovato, Gender influence the clinical presentation and long-term outcome of Graves disease. Endocr. Pract. 22, 1336\u20131342 (2016)","journal-title":"Endocr. Pract."},{"key":"1785_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-065X.1996.tb00919.x","volume":"153","author":"CA Chambers","year":"1996","unstructured":"C.A. Chambers, M.F. Krummel, B. Boitel, A. Hurwitz, T.J. Sullivan, S. Fournier, D. Cassell, M. Brunner, J.P. Allison, The role of CTLA-4 in the regulation of T-cell responses. Immunol. Rev. 153, 27\u201334 (1996)","journal-title":"Immunol. Rev."},{"key":"1785_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00251-002-0429-9","volume":"54","author":"M Ma\u00fcrer","year":"2002","unstructured":"M. Ma\u00fcrer, S. Loserth, A. Kolb-Maurer, A. Ponath, S. Wiese, N. Kruse, P. Rieckmann, A polymorphism in human cytotoxic T lymphocyte antigen 4 (CTLA-4) gene (exon 1_49) alters T cell activation. Immunogenetics 54, 1\u20138 (2002)","journal-title":"Immunogenetics"},{"key":"1785_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1210\/jc.2003-030854","volume":"89","author":"PW Wang","year":"2004","unstructured":"P.W. Wang, R.T. Liu, S.H.H. Juo, S.T. Wang, Y.H. Hu, C.J. Hsieh, M.H. Chen, I.Y. Chen, C.I. Wu, Cytotoxic T lymphocyte-associated molecule-4 polymorphism and relapse of Graves\u2019 hyperthyroidism after antithyroid withdrawal. J. Clin. Endocrinol. Metab. 89, 169\u2013173 (2004)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1785_CR21","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1089\/thy.1999.9.1089","volume":"9","author":"RV Garc\u00eda-Mayor","year":"1999","unstructured":"R.V. Garc\u00eda-Mayor, M. R\u00edos, E. Fluiters, L.F. P\u00e9rez M\u00e9ndez, E. Gonz\u00e1lez, A. Andrade, Effect of iodine supplementation on a pediatric population with mild iodine deficiency. Thyroid 9, 1089\u20131093 (1999)","journal-title":"Thyroid"},{"key":"1785_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0140-6736(99)07221-9","volume":"355","author":"S Peterson","year":"2000","unstructured":"S. Peterson, A. Sanga, H. Ekl\u00f6f, B. Bunga, A. Taube, M. Gebre-Medhin, H. Rosling, Classification of thyroid size by palpation and ultrasonografy in field surveys. Lancet 355, 106\u2013110 (2000)","journal-title":"Lancet"},{"key":"1785_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1210\/jcem-44-1-203","volume":"44","author":"AC Werner","year":"1977","unstructured":"A.C. Werner, Modification of the classification of the eye changes of Graves\u2019 disease: recommendations of the Ad Hoc Committee of American Thyroid Association. J. Clin. Endocrinol. Metabol. 44, 203\u2013204 (1977)","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"1785_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/thy.1993.3.119","volume":"3","author":"JT Dunn","year":"1993","unstructured":"J.T. Dunn, H.E. Crustchfield, R. Gutefunst, A.D. Dunn, Two simple methods for measuring iodine in urine. Thyroid 3, 119\u2013123 (1993)","journal-title":"Thyroid"},{"key":"1785_CR25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.5812\/Kowsar.1726913X.2613","volume":"9","author":"P \u00c1lvarez-V\u00e1zquez","year":"2011","unstructured":"P. \u00c1lvarez-V\u00e1zquez, L. Constenla, R.V. Garc\u00eda-Mayor, A. Larra\u00f1aga, D. Valverde, Association of CTLA4 gene polymorphism with ophthalmopathy of Graves\u2019 disease in a Spanish population. Int. J. Endocrinol. Metabol. 9, 397\u2013402 (2011)","journal-title":"Int. J. Endocrinol. Metabol."},{"key":"1785_CR26","first-page":"56","volume":"29","author":"RV Garcia-Mayor","year":"1982","unstructured":"R.V. Garcia-Mayor, P. Cobas, Resultados del tratamiento de la enfermedad de Basedow-Graves con antitiroideos: Estudio prospectivo. Endocrinologia 29, 56\u201360 (1982)","journal-title":"Endocrinologia"},{"key":"1785_CR27","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/BF03348811","volume":"15","author":"RV Garcia-Mayor","year":"1992","unstructured":"R.V. Garcia-Mayor, C. Paramo, R. Luna Cano, L.F. P\u00e9rez M\u00e9ndez, J.C. Galofr\u00e9, A. Andrade, Antithyroid drug and Graves? Hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J. Endocrinol. Invest. 15, 815\u2013820 (1992)","journal-title":"J. Endocrinol. Invest."},{"key":"1785_CR28","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s40618-016-0516-7","volume":"39","author":"L Bartalena","year":"2016","unstructured":"L. Bartalena, E. Masiello, F. Magri, G. Veronesi, E. Bianconi, F. Zerbini, M. Gaiti, E. Sprafico, D. Gallo, P. Premoli, E. Piantanida, M.L. Tanda, M. Ferrario, P. Vitti, L. Chiovato, The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J. Endocrinol. Invest. 39, 1445\u20131451 (2016)","journal-title":"J. Endocrinol. Invest."},{"key":"1785_CR29","first-page":"98","volume":"78","author":"U Feldt-Rasmussen","year":"1994","unstructured":"U. Feldt-Rasmussen, H. Schleusener, P. Carayon, Metaanalysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves\u2019 disease. J. Clin. Endocrinol. Metabol. 78, 98\u2013102 (1994)","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"1785_CR30","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"T.J. Smith, L. Hegedus, Graves\u2019 disease. N. Engl. J. Med. 375, 1552\u20131565 (2016)","journal-title":"N. Engl. J. Med."},{"key":"1785_CR31","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(11)60782-4","volume":"379","author":"JA Franklyn","year":"2012","unstructured":"J.A. Franklyn, K. Boelaert, Thyrotoxicosis. Lancet 379, 1155\u20131166 (2012)","journal-title":"Lancet"},{"key":"1785_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1210\/jcem-26-8-803","volume":"26","author":"JM Hershman","year":"1966","unstructured":"J.M. Hershman, J.R. Givens, C.E. Cassidy, E.B. Astwood, Long-term outcome of hyperthyroidism treated with antithyroid drug. J. Clin. Endocrinol. Metabol. 26, 803\u2013807 (1966)","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"Suppl. 185","key":"1785_CR33","first-page":"3","volume":"115","author":"D Glinoer","year":"1986","unstructured":"D. Glinoer, D. Hesch, R. Lagasse, P. Lauberg, The management of hyperthyroidism due to Graves\u2019 disease in Europe in 1987. Acta Endocrinol. 115(Suppl. 185), 3\u201323 (1986)","journal-title":"Acta Endocrinol."},{"key":"1785_CR34","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1210\/jc.2015-3644","volume":"101","author":"XG Vos","year":"2016","unstructured":"X.G. Vos, E. Endert, A.H. Zwindermena, J.G.P. Tijssen, W.M. Wiersinga, Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves\u2019 hyperthyroidism. J. Clin. Endocrinol. Metabol. 101, 1381\u20131389 (2016)","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"1785_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/thy.1997.7.369","volume":"7","author":"P Vitti","year":"1997","unstructured":"P. Vitti, T. Rago, L. Chiovato, S. Pallini, F. Santini, E. Fiore, R. Rocchi, E. Martino, A. Pinchera, Clinical features of patients with Graves\u2019 disease undergoing remission after antithyroid drug treatment. Thyroid 7, 369\u2013375 (1997)","journal-title":"Thyroid"},{"key":"1785_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/BF03343979","volume":"25","author":"LE Kimball","year":"2002","unstructured":"L.E. Kimball, E. Kulinskaya, B. Brown, C. Johnson, N.R. Farid, Does smoking increase relapse rates in Graves\u2019 disease? J. Endocrinol. Invest. 25, 152\u2013157 (2002)","journal-title":"J. Endocrinol. Invest."},{"key":"1785_CR37","first-page":"175","volume":"66","author":"ET Young","year":"1988","unstructured":"E.T. Young, N.R. Steel, J.J. Taylor, A.M. Stephenson, A. Stratton, M. Holcombe, P. Kendall-Taylor, Prediction of remission after antithyroid drug treatment in Graves\u2019 disease. Q. J. Med. 66, 175\u2013189 (1988)","journal-title":"Q. J. Med."},{"key":"1785_CR38","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1046\/j.1365-2265.1998.00554.x","volume":"49","author":"G Benker","year":"1998","unstructured":"G. Benker, D. Reinwein, G. Kahaly, L. Tegler, W.D. Alexander, J. Fassbinder, H. Hirch, Is there a methimazole dose effect on remission rate in Graves\u2019 disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of hyperthyroidism with antithyroid drugs. Clin. Endocrinol. 49, 451\u2013458 (1998)","journal-title":"Clin. Endocrinol."},{"key":"1785_CR39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000342621","volume":"1","author":"PW Wang","year":"2012","unstructured":"P.W. Wang, I.Y. Chen, S.H. Hank Juo, E. Hsi, R.T. Liu, C.J. Hsieh, Genotype and phenotype predictors of relapse of Graves\u2019 disease after antithyroid drug withdrawal. Eur. Thyroid J. 1, 251\u2013258 (2012)","journal-title":"Eur. Thyroid J."},{"key":"1785_CR40","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1089\/thy.2016.0017","volume":"26","author":"NNZ Tun","year":"2016","unstructured":"N.N.Z. Tun, G. Beckett, N.N. Zammnitt, M.W.J. Strachan, J.R. Seckl, G.W. Gibb, Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves\u2019 disease relapse. Thyroid 26, 1004\u20131009 (2016)","journal-title":"Thyroid"},{"key":"1785_CR41","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/bmj.298.6670.359","volume":"298","author":"G Edan","year":"1989","unstructured":"G. Edan, C. Massart, N.Y. Poirier, M. L\u00e9 Reun, J.P. Hespel, G. Leclech, M. Simon, Optimun duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves\u2019 disease. BMJ 298, 359\u2013361 (1989)","journal-title":"BMJ"},{"key":"1785_CR42","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1210\/jcem-68-6-1097","volume":"68","author":"Y Takaichi","year":"1989","unstructured":"Y. Takaichi, H. Tamai, K. Honda, K. Nagai, K. Kuma, T. Nakagawa, The significance of antithyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves\u2019 disease treated with antithyroid drugs. J. Clin. Endocrinol. Metabol. 68, 1097\u20131100 (1989)","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"1785_CR43","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02933.x","volume":"67","author":"AK Eckstein","year":"2007","unstructured":"A.K. Eckstein, H. Lax, C. L\u00f6sch, D. Glowacka, M. Plicht, K. Mann, J. Esser, N.G. Morgenthaler, Patients with severe Graves\u2019 ophthalmopathy have a higher risk of relalsing hyperthyroidism and are unlikely to remain in remission. Clin. Endocrinol. 67, 607\u2013612 (2007)","journal-title":"Clin. Endocrinol."},{"key":"1785_CR44","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1210\/jc.2006-2761","volume":"91","author":"PW Wang","year":"2007","unstructured":"P.W. Wang, R.T. Liu, S.H.H. Juo, S.E. Wang, Y.H. Hu, C.J. Hsieli, M.H. Chen, I.Y. Chen, C.L. Wu, Cytotoxic T lymphocyte-associated molecule-4 polymorphism and relapse of Graves\u2019 hyperthyroidism after antithyroid withdrawal: a follow-up study. J. Clin. Endocrinol. Metab. 91, 2513\u20132518 (2007)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1785_CR45","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12020-006-0017-0","volume":"30","author":"S Tanrikulu","year":"2006","unstructured":"S. Tanrikulu, Y. Erbil, E. Ademoglu, H. Issever, U. Barbaros, F. Kutkuturk, S. Ozarmagan, S. Tezelman, The predictive value of CTLA4 and Tg polimorphisms in the recurrence of Graves\u2019 disease after antithyroid withdrawal. Endocrine 30, 377\u2013381 (2006)","journal-title":"Endocrine"},{"issue":"Suppl. 4","key":"1785_CR46","first-page":"98","volume":"104","author":"KW Kim","year":"1996","unstructured":"K.W. Kim, Y.J. Park, T.Y. Kim, D.J. Park, B.Y. Cho, K. Badenhoop, H. Donner, J. Braun, T. Siegmund, H. Raud, K.H. Usadel, Genetic markers in diagnosis and prediction of relapse in Graves\u2019 disease. Exp. Clin. Endocrinol. Diabetes 104(Suppl. 4), 98\u2013100 (1996)","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"1785_CR47","doi-asserted-by":"publisher","unstructured":"E. Masiello, G. Vernonesi, D. Gallo, P. Premoli, E. Bianconi, S. Rosetti, C. Cusini, J. Sabatino, S. Ippolito, E. Piantanida, M.L. Tanda, L. Chiovato, W.M. Wiersinga, L. Bartalena. Antithyroid drug treatment for Graves\u2019 disease: baseline predictive models of relapse after treatment for a patient-tailored management. J. Endocrinol. Invest. (2018). https:\/\/doi.org\/10.1007\/s40618-018-0918-9","DOI":"10.1007\/s40618-018-0918-9"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-018-1785-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1785-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1785-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T13:02:34Z","timestamp":1720702954000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-018-1785-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1785"],"URL":"https:\/\/doi.org\/10.1007\/s12020-018-1785-z","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,17]]},"assertion":[{"value":"14 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Research Ethics Committee of the Autonomous Government of Galicia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants gave their consent after being verbally informed about the nature and purpose of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}